BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF)'s Chief executive Tiffany Thorn talks to Proactive London about their method and adding two potential cancer therapies to its pipeline - BVX002 and BVX003.
They join BVX001, a putative treatment for acute myeloid leukaemia. She says their focused on working to fast-track the development of these two new programmes alongside our lead asset, BVX001, to reach early preclinical proof of concept in the short to medium term.